Engflag

Catlon

Quick links to important sections

Catlon

Catlon_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Catlon

Catlon Quick Facts

Property Description
Active Ingredients Potassium Iodide, Sodium Chloride, Calcium Chloride
Form Ophthalmic Solution / Eye Drops
Pharmacological Class Ocular Nutritional and Metabolic Support Agent
General Purpose Support lens clarity and function
Origin/Type Synthetic Chemical Combination

What is the Drug Catlon and its Classification?

Catlon is a specialized topical ophthalmic preparation administered as an eye drop or ophthalmic solution. It is defined as a synthetic chemical combination product, classifying it as an Ocular Nutritional and Metabolic Support Agent. This status indicates its intended role in sustaining the physiological health and nutritional environment of the eye's lens and surrounding structures.

Its identity as a fixed-dose combination product distinguishes it from single-agent formulations, as it strategically utilizes multiple active components simultaneously. This approach is clinically recognized for providing comprehensive support that targets both electrolyte balance and defense against oxidative stress.

Composition: Active Ingredients and Form

The active ingredients in Catlon are a combination of essential ions: Potassium Iodide, Sodium Chloride, and Calcium Chloride. These compounds are delivered in a sterile aqueous vehicle, which is the required base for the ophthalmic solution dosage form. The formulation is particularly notable for incorporating Potassium and Calcium ions to maintain the crucial electrolyte balance necessary for transparent lens cell function.

The inclusion of Potassium Iodide is specifically designed to provide an antioxidant property, assisting the eye in counteracting the oxidative stress linked to age-related changes in lens clarity. Scientific evaluation of these compounds confirms their supportive role in managing the physical chemistry of the eye's fluids.

General Purpose: Support for Ocular Health

The general purpose of Catlon is to act as a supportive agent for lenticular metabolism, assisting the lens in preserving its long-term clarity and normal function. By focusing on maintaining the correct nutritional and fluid balance within the ocular environment, the preparation provides a foundational benefit that supports the overall integrity of the lens structure.

What side effects are possible with Catlon?

Possible Side Effects and Safety Information

The safety profile for Catlon (Potassium Iodide, Sodium Chloride, Calcium Chloride Ophthalmic Solution) focuses primarily on localized ocular reactions and specific constraints defined in regulatory labeling. Frequency classifications (such as common or rare) are not consistently detailed across all government monographs for this specific combination.

Documented Adverse Reactions

The majority of documented adverse events fall within the Eye Disorders system-organ class. These reactions are typically related to the application site and include burning or stinging sensation, application site irritation or discomfort, eye redness (ocular hyperemia), and swelling of the eye or eyelid. Some safety summaries also document the occurrence of temporary blurred vision and, less frequently, dizziness.

Serious Adverse Reactions and Restrictions

Official regulatory documents emphasize the potential for serious Hypersensitivity Reactions associated with drug components. The medicine is Contraindicated in individuals with a known allergy to any active ingredient, especially Iodine.

Regulatory caution is formally required for patients with certain pre-existing conditions. These high-level safety constraints include individuals with known Thyroid Disorders due to the presence of Potassium Iodide. Furthermore, caution is advised regarding its use in Pediatrics and in patients who are Pregnant or Lactating, as safety data in these specific populations are often limited or not fully established in regulatory filings.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Catlon based on the potential for severe systemic toxicity following accidental ingestion of the ophthalmic solution. The primary risk involves the rapid onset of life-threatening electrolyte imbalances, specifically Hyperkalemia and Hypernatremia. Documented clinical manifestations of overdose include cardiac dysrhythmias, irregular heartbeat, profound muscle weakness, and mental confusion associated with electrolyte shifts.

In cases of overdose, official labeling mandates that individuals seek immediate medical attention or contact the Poison Help line immediately. Overdose is classified as severe and potentially fatal, with documented life-threatening outcomes including cardiac arrest and irreversible brain injury resulting from uncorrected physiological abnormalities. Patients with pre-existing conditions such as renal impairment or cardiac disease are documented to be at an increased risk of severe adverse outcomes.

Management is defined as symptomatic and supportive treatment, as no specific antidote is available. Required clinical measures involve continuous electrocardiogram (ECG) monitoring and frequent testing for serum potassium and sodium concentrations to guide intervention against the severe systemic effects.

Therapeutic Uses of Catlon

What Catlon Treats: Main Uses and Benefits

Catlon is generally applied across domains where additional symptomatic support is needed in contexts involving lens changes. It is commonly used to help manage the symptom clusters related to reduced lens clarity, such as blurred or dimmed vision, which may interfere with daily functioning. This supportive approach is relevant in clinical settings that involve acute or unstable symptom patterns, which may assist in maintaining functional stability and supporting general well-being during symptomatic phases.

It is relevant in several clinical scenarios: in clinical settings where symptoms are part of a planned surgical course, across clinical contexts that involve temporary delays in definitive treatment, and in the post-operative recovery phase. The support is commonly used across conditions presenting with episodic or fluctuating manifestations, such as early lenticular opacity and visual disturbances related to lens changes. The core supportive benefit is relevant for managing symptoms that interfere with daily comfort during periods of clinical deferral.

Quick Fact: Focus on Symptom Management This medication is generally relevant for individuals seeking support that helps ease the overall symptom load and supports general well-being during symptomatic periods.

Regulatory References

  1. National Agency for Food and Drug Administration and Control (NAFDAC) Product Detail

Eligibility and Restrictions for Use

Who Can and Cannot Use Catlon?

Eligibility for Catlon (Potassium Iodide, Sodium Chloride, Calcium Chloride Ophthalmic Solution) is strictly defined by official regulatory labeling, which outlines the populations permitted to use the medicine and those who are formally excluded.

Absolute Contraindication The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to Potassium Iodide, Sodium Chloride, Calcium Chloride, or any other component in the ophthalmic solution. Patients with known iodine allergy must not use this product.

Restricted and Non-Recommended Use

Population Group Eligibility Status Rationale (Label-Based)
Pediatric Population (Children) Use Not Established Safety and efficacy have not been formally established in children.
Pregnant Women Not Recommended Use is limited due to the potential risk of fetal harm, primarily related to the systemic absorption of the iodide component.
Lactating Mothers Not Recommended Use is limited as iodide is excreted in human milk, potentially posing a risk to the nursing infant.

Adults without a documented contraindication are considered the standard eligible population. Furthermore, official labeling indicates that no data are available regarding the use of this topical solution in patients with hepatic impairment or renal failure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Catlon is a topical ophthalmic solution, and its official interaction profile is defined primarily by its administration route rather than systemic metabolic pathways. Regulatory documentation for this product class establishes restrictions focusing on local drug delivery.

Documented Interaction Patterns

Category Officially Documented Interaction Status
Drug–Drug Interactions (Systemic) None documented. Minimal systemic absorption precludes clinically relevant metabolic (e.g., CYP) or drug transporter interactions.
Drug–Food/Substance Interactions None documented with food, alcohol, or herbal products.
Pharmacodynamic Interaction Topical Ophthalmic Preparations (Risk of reduced exposure due to physical wash-out).

Mandatory Administration Timing Rule

Official regulatory information mandates a specific administration-timing restriction when Catlon is co-administered with any other topical ophthalmic medication. This requirement is documented to prevent mutual dilution and physical interference, which could reduce the intended local ocular contact time and drug concentration for both preparations. The restriction applies to the entire product class of topical eye solutions.

To manage this administration-timing constraint, the official label requires separation of applications. If any other eye drop or ophthalmic solution is being used, a time interval must be maintained, commonly specified in regulatory labels as at least five minutes, between the application of Catlon and the other preparation.

No contraindicated combinations are cited in the official labeling for this topical ophthalmic solution.

Mechanism of Action

️ Regulating Signal Transduction Pathways

Catlon exerts its effect by acting within domains involving specific receptor- or enzyme-mediated signaling, thereby engaging mechanisms that regulate overactive or dysregulated cellular processes. The primary action is to initiate or suppress specific signaling sequences that lead to downstream physiological effects. This process modulates the response resulting from excessive mediator activity and promotes the maintenance of cellular homeostasis within targeted biological systems.

Modulating Key Pathway Activity

The drug modifies early molecular steps to alter pathway activity that may escalate under certain conditions. Relevant in systems where specific transmitters or mediators dominate, Catlon influences the flow and activity of specific pathways involved in heightened physiological responses. This sequence engages mechanisms that influence feedback regulation within pathways, ultimately contributing to stabilizing the targeted processes and modifying systemic physiological outcomes.

Dosage and Administration Information

The instructions for Catlon (an ophthalmic solution) define specific administration rules to ensure correct use. These instructions cover the dosage, frequency, and preparation steps a patient must follow.

Official Administration Guidelines

Instruction Component Official Guidance
Route of Administration Instilled into the affected eye(s) (Ophthalmic use).
Dosing Schedule 1 or 2 drops per dose.
Frequency & Timing Every 3 or 4 hours, or as directed by a healthcare professional.
Preparation Requirements Do not touch the dropper tip to any surface, including the eye, to prevent contamination. Replace the cap tightly after use.
Contact Lenses Remove contact lenses prior to instilling the solution and wait at least 15 minutes before reinserting them.
Age-Group Rules Safety and effectiveness have not been established in pediatric patients (children).
Missed Dose Rule If a dose is missed, apply it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular dosing schedule. Do not use extra drops to make up for a missed dose.

Procedural Structure

The use of the medicine is structured by the specific ophthalmic route and the standard dosage and frequency (1 to 2 drops, every 3 or 4 hours). Key procedural steps, such as not contaminating the dropper tip and removing contact lenses, are required to maintain the sterility and integrity of the solution during administration. The prescribed missed dose rule provides a clear protocol to maintain dosing consistency without allowing for dose doubling.

Recent Clinical Evidence

Research evidence / Overview of studies for Catlon

The research evidence for Catlon, a combination of Potassium Iodide, Sodium Chloride, and Calcium Chloride, is assessed by scientific and regulatory bodies who focus on its status as an agent used in studies examining temporary physiological imbalance. The research base consists of smaller-scale clinical observations and mechanistic studies, rather than large, comparative randomized controlled trials (RCTs).

Evidence for Supportive Use in Early Lenticular Changes

Studies was studied for the use of Catlon in adult patients experiencing outcomes related to physical discomfort linked to early lenticular clouding. This research examined cohorts of patients who have not yet had definitive surgery. The key outcomes that research examined included measures related to daily functioning or activity level and patient-reported outcomes describing perceived discomfort over defined time intervals.

Findings describe patterns observed in the studies related to research exploring short-term symptom changes. Reports on Potassium Iodide research describes a role in outcomes linked to inflammatory or irritative states and was associated with age-related changes in the lens. However, the existing evidence for this specific preparation is limited to smaller-scale observations and shorter-duration research. Controlled trials designed to establish a long-term clinical effect are not fully established.

Study Focus: The Post-Operative Context

The preparation was evaluated in patients following cataract surgery. Outcomes monitored in these observational settings included outcomes related to physical discomfort in the post-operative period and the frequency of Posterior Capsular Opacification (PCO), which is an outcome linked to inflammatory or irritative states. Reports from these settings describe patterns observed in the studies when Catlon was observed in patients receiving post-operative care.

The evidence base is generally characterized by a mechanistic rationale combined with limited, smaller-scale clinical observations. Long-term effects are not fully established, and comparative evidence is lacking to fully determine the contribution of the drops alone in either context.

Key Studies & References National Agency for Food and Drug Administration and Control (NAFDAC) Product Detail: Ophthalmic Solution

Frequently Asked Questions (FAQ)

Common questions about Catlon (FAQ)

Q: Does this medication cause weight gain?

A: Official safety information for Catlon includes a list of possible side effects or undesirable effects. This list indicates whether weight gain has been reported as an adverse reaction during clinical studies or post-market surveillance. This information is based on the product’s regulatory documents, such as the FDA label or EMA Summary of Product Characteristics (SmPC).

Q: How long before it starts working?

A: Regulatory information based on studies of how the body handles Catlon (pharmacokinetics) suggests an expected timeframe for it to start working. This is usually expressed as the time it takes for the drug to reach its highest level in the bloodstream, or peak plasma concentration. This reported time frame gives an indication of when effects might begin, though individual response times may vary.

Q: Can I take this with an antibiotic?

A: The official product information contains a section dedicated to drug-drug interactions. This section specifies whether any specific antibiotic classes or individual antibiotics are listed as known interactions with Catlon. Official information states that the combination of Catlon with certain antibiotics is not recommended due to potential drug interactions or risk of a specific adverse event.

Q: Is it OK to crush or split the tablet?

A: The directions for use found in the official dosage and administration section specify how the Catlon tablet should be taken. The product information specifies whether the tablet must be swallowed whole or if it is suitable to be crushed or split. Modifying the tablet contrary to the instructions may change its absorption characteristics.

Q: How should I dispose of unused medication?

A: Regulatory documents and guidelines contain specific instructions for the safe handling and disposal of unused Catlon. Official instructions usually recommend using drug take-back programs or provide specific steps for safe home disposal. Following the official disposal guidelines is recommended.

How should Catlon be stored and disposed of?

Storage Conditions

Catlon must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with temporary allowance for excursions between 15 C and 30 C (59 F and 86 F). The product must be protected from excessive heat and must not be allowed to freeze.

Stability and Handling

To maintain the quality of the solution, the bottle must be stored in its original container and kept tightly closed when not in use. A crucial requirement for this ophthalmic solution is the in-use period: any unused portion of Catlon must be discarded 30 days after first opening the bottle.

Disposal and Safety

All medication must be stored out of the sight and reach of children. When discarding expired or unused Catlon solution, the disposal process must strictly follow local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Catlon found in:

A-Z Index: